- TV Footage
- Integrated Annual Reports
- Quarterly Statements
- Sustainability Report
- Newsletter Overview
- Social Media
- Media Contact
Berlin / Vienna, February 28, 2019 – Bayer today revealed its new MEDRAD™ Centargo CT injection system at this year’s European Congress of Radiology (ECR) 2019, taking place from February 27 – March 3 in Vienna. The latest addition to Bayer’s range of imaging products, which is expected to receive CE certification this summer, has been developed with the aim of meeting one of the most pressing needs of radiology departments today: doing more with less.
“With a continuously increasing number of patients and sometimes quite complex CT procedures, what we need are product innovations that simplify our workflow and allow us to focus on the quality of the image and most importantly the patient,” said Dr. Casper Mihl, Head of the CT Department and Abdominal and Cardiovascular Radiologist at Maastricht University Medical Center.
Key features of MEDRAD Centargo include a daily set-up process that can be completed in under 2 minutes and a snap-in patient line that is ready for the next patient in less than 20 seconds. Furthermore, the piston-based technology of Centargo has been designed to provide quality fluid delivery, even during the most demanding protocols. The integrated barcode reader reduces manual data entry and provides easy traceability and access to contrast and injection details. Further details on Centargo’s features can be found in the MEDRAD Centargo factsheet available here.
“We have been working in partnership with radiologists to create a new CT injector that meets the demands faced by modern radiology departments,” said Prof. Dr. Olaf Weber, Head of Radiology Research and Development at Bayer. “Centargo offers innovative technology and design that increase efficiency and improve workflow through less manual work and touch time, allowing Radiology teams to spend more time where it matters most – with their patients.”
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros. For more information, go to www.bayer.com.
To learn more about Bayer in Radiology, visit radiology.bayer.com/
Find more information at www.pharma.bayer.com
Follow us on Facebook: www.facebook.com/pharma.bayer
Follow us on Twitter: @BayerPharma
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
View Download Center